RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

TEL AVIV, Israel and RALEIGH, NC, October 14, 2020, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to

‘Significant’ COVID-19 drug breakthrough

A new inhalation treatment for preventing the spread of COVID-19 is potentially far more effective than currently existing versions, according to new research carried out at the University of St Andrews. ILC Therapeutics, a Scottish